《心力衰竭合理用药指南(第2版)》

2019-07-23

第2版《心力衰竭合理用药指南》涵盖心衰发生、发展的全过程,更新了慢性射血分数降低的心衰诊断、治疗流程,急性心衰的治疗流程,合并症的治疗等;在慢性射血分数降低的心衰药物治疗中,增加了血管紧张素受体脑啡肽酶抑制剂的推荐;阐述了心衰的病因、预防及危险因素的管理,强调重在预防的防控策略;结合我国现实,对如何实施有效的心衰管理进行阐述,增加了肿瘤治疗相关性心功能不全、老年心衰的管理、妊娠合并心衰的治疗、高原

中文标题:

《心力衰竭合理用药指南(第2版)》

发布机构:

发布日期:

2019-07-23

简要介绍:

第2版《心力衰竭合理用药指南》涵盖心衰发生、发展的全过程,更新了慢性射血分数降低的心衰诊断、治疗流程,急性心衰的治疗流程,合并症的治疗等;在慢性射血分数降低的心衰药物治疗中,增加了血管紧张素受体脑啡肽酶抑制剂的推荐;阐述了心衰的病因、预防及危险因素的管理,强调重在预防的防控策略;结合我国现实,对如何实施有效的心衰管理进行阐述,增加了肿瘤治疗相关性心功能不全、老年心衰的管理、妊娠合并心衰的治疗、高原性心脏病等。通过修订,使得本指南具有更好的实用性和实践性。在文字阐述的基础上,应用图表和流程图的形式,如射血分数降低的心衰诊断和治疗流程、急性心衰的治疗流程、急性右心衰的治疗流程,心衰常用药物一览表、药物相互作用一览表,使内容一目了然,便于临床医生的学习。我们希望新版《心力衰竭合理用药指南》能够帮助医生根据患者的病情,基于最好的循证医学证据,制定恰当的诊疗策略和方案,选择恰当、合理的药物及剂量,改善患者的症状,减少住院和死亡的风险,从而提高我国心衰的整体防控水平,优化医疗资源的使用。

相关资料下载:
[AttachmentFileName(sort=100, fileName=《心力衰竭合理用药指南(第2版)》)] GetToolGuiderByIdResponse(projectId=1, id=bf8c91c001e6a5d0, title=《心力衰竭合理用药指南(第2版)》, enTitle=, guiderFrom=, authorId=null, author=, summary=第2版《心力衰竭合理用药指南》涵盖心衰发生、发展的全过程,更新了慢性射血分数降低的心衰诊断、治疗流程,急性心衰的治疗流程,合并症的治疗等;在慢性射血分数降低的心衰药物治疗中,增加了血管紧张素受体脑啡肽酶抑制剂的推荐;阐述了心衰的病因、预防及危险因素的管理,强调重在预防的防控策略;结合我国现实,对如何实施有效的心衰管理进行阐述,增加了肿瘤治疗相关性心功能不全、老年心衰的管理、妊娠合并心衰的治疗、高原, cover=, journalId=null, articlesId=null, associationId=null, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Tue Jul 23 17:56:56 CST 2019, originalUrl=, linkOutUrl=, content=<span style="color: rgb(29, 29, 29); font-family: -apple-system-font, BlinkMacSystemFont, " helvetica="" neue",="" "pingfang="" sc",="" "hiragino="" sans="" gb",="" "microsoft="" yahei="" ui",="" yahei",="" arial,="" sans-serif;="" font-size:="" 14px;="" font-style:="" normal;="" font-variant-ligatures:="" font-variant-caps:="" font-weight:="" letter-spacing:="" 0.544px;="" orphans:="" 2;="" text-align:="" justify;="" text-indent:="" 0px;="" text-transform:="" none;="" white-space:="" widows:="" word-spacing:="" -webkit-text-stroke-width:="" background-color:="" rgb(255,="" 255,="" 255);="" display:="" inline="" !important;="" float:="" none;"="">第2版《心力衰竭合理用药指南》涵盖心衰发生、发展的全过程,更新了慢性射血分数降低的心衰诊断、治疗流程,急性心衰的治疗流程,合并症的治疗等;在慢性射血分数降低的心衰药物治疗中,增加了血管紧张素受体脑啡肽酶抑制剂的推荐;阐述了心衰的病因、预防及危险因素的管理,强调重在预防的防控策略;结合我国现实,对如何实施有效的心衰管理进行阐述,增加了肿瘤治疗相关性心功能不全、老年心衰的管理、妊娠合并心衰的治疗、高原性心脏病等。通过修订,使得本指南具有更好的实用性和实践性。在文字阐述的基础上,应用图表和流程图的形式,如射血分数降低的心衰诊断和治疗流程、急性心衰的治疗流程、急性右心衰的治疗流程,心衰常用药物一览表、药物相互作用一览表,使内容一目了然,便于临床医生的学习。我们希望新版《心力衰竭合理用药指南》能够帮助医生根据患者的病情,基于最好的循证医学证据,制定恰当的诊疗策略和方案,选择恰当、合理的药物及剂量,改善患者的症状,减少住院和死亡的风险,从而提高我国心衰的整体防控水平,优化医疗资源的使用。</span>, tagList=[TagDto(tagId=335, tagName=心力衰竭), TagDto(tagId=207, tagName=用药), TagDto(tagId=63, tagName=指南)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=61, categoryName=医学教育, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=8616, appHits=1395, showAppHits=21, pcHits=3917, showPcHits=4806, likes=110, shares=98, comments=21, approvalStatus=1, publishedTime=Tue Jul 23 17:56:56 CST 2019, publishedTimeString=2019-07-23, pcVisible=1, appVisible=1, editorId=5296068, editor=qi.yuan, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qi.yuan, createdTime=Tue Jul 23 17:56:56 CST 2019, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 21:21:40 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=《心力衰竭合理用药指南(第2版)》)])
《心力衰竭合理用药指南(第2版)》
下载请点击:
评论区 (16)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1082807, encodeId=9dec108280ecc, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd315253200, createdName=147e71c7m18暂无昵称, createdTime=Tue Dec 21 23:29:15 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057580, encodeId=ef6e105e58093, content=谢谢,学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ad901494890, createdName=dr-jin, createdTime=Mon Oct 04 14:32:01 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974000, encodeId=800e9e40004e, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=27165136786, createdName=14669a9cm19暂无昵称, createdTime=Wed Jun 16 08:45:35 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958482, encodeId=3c6a9584822d, content=分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200831/fb689c3e816d4a64820d63f72073eef4/29c665e5fc1341a9ae58ecf5b979aef9.jpg, createdBy=7e215414767, createdName=ANNA1, createdTime=Mon Apr 19 20:08:36 CST 2021, time=2021-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951601, encodeId=35b095160145, content=分享了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4ab2205971, createdName=120c570cm03暂无昵称, createdTime=Sat Mar 27 13:41:46 CST 2021, time=2021-03-27, status=1, ipAttribution=)]
    2021-12-21 147e71c7m18暂无昵称

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1082807, encodeId=9dec108280ecc, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd315253200, createdName=147e71c7m18暂无昵称, createdTime=Tue Dec 21 23:29:15 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057580, encodeId=ef6e105e58093, content=谢谢,学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ad901494890, createdName=dr-jin, createdTime=Mon Oct 04 14:32:01 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974000, encodeId=800e9e40004e, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=27165136786, createdName=14669a9cm19暂无昵称, createdTime=Wed Jun 16 08:45:35 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958482, encodeId=3c6a9584822d, content=分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200831/fb689c3e816d4a64820d63f72073eef4/29c665e5fc1341a9ae58ecf5b979aef9.jpg, createdBy=7e215414767, createdName=ANNA1, createdTime=Mon Apr 19 20:08:36 CST 2021, time=2021-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951601, encodeId=35b095160145, content=分享了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4ab2205971, createdName=120c570cm03暂无昵称, createdTime=Sat Mar 27 13:41:46 CST 2021, time=2021-03-27, status=1, ipAttribution=)]
    2021-10-04 dr-jin

    谢谢,学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1082807, encodeId=9dec108280ecc, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd315253200, createdName=147e71c7m18暂无昵称, createdTime=Tue Dec 21 23:29:15 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057580, encodeId=ef6e105e58093, content=谢谢,学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ad901494890, createdName=dr-jin, createdTime=Mon Oct 04 14:32:01 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974000, encodeId=800e9e40004e, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=27165136786, createdName=14669a9cm19暂无昵称, createdTime=Wed Jun 16 08:45:35 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958482, encodeId=3c6a9584822d, content=分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200831/fb689c3e816d4a64820d63f72073eef4/29c665e5fc1341a9ae58ecf5b979aef9.jpg, createdBy=7e215414767, createdName=ANNA1, createdTime=Mon Apr 19 20:08:36 CST 2021, time=2021-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951601, encodeId=35b095160145, content=分享了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4ab2205971, createdName=120c570cm03暂无昵称, createdTime=Sat Mar 27 13:41:46 CST 2021, time=2021-03-27, status=1, ipAttribution=)]
    2021-06-16 14669a9cm19暂无昵称

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1082807, encodeId=9dec108280ecc, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd315253200, createdName=147e71c7m18暂无昵称, createdTime=Tue Dec 21 23:29:15 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057580, encodeId=ef6e105e58093, content=谢谢,学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ad901494890, createdName=dr-jin, createdTime=Mon Oct 04 14:32:01 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974000, encodeId=800e9e40004e, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=27165136786, createdName=14669a9cm19暂无昵称, createdTime=Wed Jun 16 08:45:35 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958482, encodeId=3c6a9584822d, content=分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200831/fb689c3e816d4a64820d63f72073eef4/29c665e5fc1341a9ae58ecf5b979aef9.jpg, createdBy=7e215414767, createdName=ANNA1, createdTime=Mon Apr 19 20:08:36 CST 2021, time=2021-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951601, encodeId=35b095160145, content=分享了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4ab2205971, createdName=120c570cm03暂无昵称, createdTime=Sat Mar 27 13:41:46 CST 2021, time=2021-03-27, status=1, ipAttribution=)]
    2021-04-19 ANNA1

    分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1082807, encodeId=9dec108280ecc, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd315253200, createdName=147e71c7m18暂无昵称, createdTime=Tue Dec 21 23:29:15 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057580, encodeId=ef6e105e58093, content=谢谢,学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ad901494890, createdName=dr-jin, createdTime=Mon Oct 04 14:32:01 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974000, encodeId=800e9e40004e, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=27165136786, createdName=14669a9cm19暂无昵称, createdTime=Wed Jun 16 08:45:35 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958482, encodeId=3c6a9584822d, content=分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200831/fb689c3e816d4a64820d63f72073eef4/29c665e5fc1341a9ae58ecf5b979aef9.jpg, createdBy=7e215414767, createdName=ANNA1, createdTime=Mon Apr 19 20:08:36 CST 2021, time=2021-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951601, encodeId=35b095160145, content=分享了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4ab2205971, createdName=120c570cm03暂无昵称, createdTime=Sat Mar 27 13:41:46 CST 2021, time=2021-03-27, status=1, ipAttribution=)]
    2021-03-27 120c570cm03暂无昵称

    分享了

    0